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Abstract
Objective
Thrombin-activatable fibrinolysis inhibitor (TAFI) reduces the breakdown of fibrin clots
through its action as an indirect inhibitor of plasmin. Studies in TAFI-deficient mice have
implicated a potential role for TAFI in Abdominal Aortic Aneurysm (AAA) disease. The role
of TAFI inhibition on AAA formation in adult ApoE-/- mice is unknown. The aim of this paper
was to investigate the effects of TAFI inhibition on AAA development and progression.
Methods
Using the Angiotensin II model of AAA, male ApoE-/- mice were infused with Angiotensin II
750ng/kg/min with or without a monoclonal antibody inhibitor of plasmin-mediated activation
of TAFI, MA-TCK26D6, or a competitive small molecule inhibitor of TAFI, UK-396082.
Results
Inhibition of TAFI in the Angiotensin II model resulted in a decrease in the mortality associ-
ated with AAA rupture (from 40.0% to 16.6% with MA-TCK26D6 (log-rank Mantel Cox test
p = 0.16), and 8.3% with UK-396082 (log-rank Mantel Cox test p = 0.05)). Inhibition of plas-
min-mediated TAFI activation reduced the incidence of AAA from 52.4% to 30.0%. How-
ever, late treatment with MA-TCK26D6 once AAA were already established had no effect on
the progression of AAA in this model.
Conclusions
The formation of intra-mural thrombus is responsible for the dissection and early rupture in
the angiotensin II model of AAA, and this process can be prevented through inhibition of
TAFI. Late treatment with a TAFI inhibitor does not prevent AAA progression. These data
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may indicate a role for inhibition of plasmin-mediated TAFI activation in the early stages of
AAA development, but not in its progression.
Introduction
An Abdominal Aortic Aneurysm (AAA) is a permanent, focal dilatation of the descending
abdominal aorta. It most commonly occurs in men over the age of 65 years [1]. The natural
history of an AAA is expansion with eventual rupture, and, despite an apparent global decrease
in rupture rate [2], ruptured AAA is still responsible for over 8000 deaths per annum in the
USA [3]. Large AAA are characteristically accompanied by the presence of an intra-luminal
thrombus (ILT) [4]. The ILT is an independent risk factor for expansion and rupture of AAA,
and, through the action of plasmin- and metalloproteinase-mediated proteolysis, is thought to
directly contribute to the breakdown of the underlying aortic wall [5]. Even beyond the ILT,
there is evidence of systemic changes in clotting in patients with AAA. In line with a number
of cardiovascular disease states, including myocardial infarction, stroke and peripheral arterial
disease [6], patients with AAA develop denser ex-vivo clots which are more resistant to lysis
[7]. The exact mechanism for this change, and whether this represents cause or effect of under-
lying cardiovascular disease states, remains to be elucidated. There is evidence for a general-
ized increase in fibrinolytic activity in this group of patients, with elevated plasma levels of
plasmin-antiplasmin complexes (PAP) [8], D-dimer, thrombin-antithrombin (TAT) and pro-
thrombin fragments F1+2 [9]. Occlusion of the aneurysm sac, as occurs through endovascular
repair, does not result in the reduction of these parameters back to normal levels [10], implying
that there is an ongoing pathological phenotype in this patient group which occurs beyond the
simple presence of an AAA. What is known, however, is that patients with AAA are frequently
affected by other atherothombotic cardiovascular diseases, in particular coronary artery dis-
ease, and independent of all other risk factors remain at an increased risk of cardiovascular
death [11].
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a physiological inhibitor of plasmin-
mediated fibrinolysis. By cleaving C-terminal lysine residues from partially degraded fibrin
molecules, activated TAFI (TAFIa) prevents the co-localisation of plasminogen and tPA onto
the surface of the fibrin clot, thereby reducing the production of plasmin, and thus inhibiting
fibrin clot breakdown [12]. TAFIa also has anti-inflammatory properties, and through its
cleavage of C3a, C5a, thrombin-cleaved osteopontin (OPN) and bradykinin, acts to counteract
some of the inflammatory sequelae of thrombin activation in-vivo [13]. TAFI has become a
popular target for new anti-thrombotic agents, with a series of antibodies, nanobodies and
small molecule inhibitors being developed against TAFI [14–16]. These include monoclonal
antibody inhibitors such as MA-TCK26D6, which specifically inhibits plasmin-mediated acti-
vation of TAFI, and has been shown to reduce thromboembolism in-vivo in a murine model
[17], and, in a diabody confirmation with a plasminogen-activator inhibitor-1 (PAI-1) anti-
body, effectively reduced lesion size and improved functional outcomes in a stroke model [18].
Evidence for a potential role for TAFI in AAA has largely been inferred from a single study in
TAFI knockout mice, which developed larger aneurysms that were more prone to ruptures,
upon porcine pancreatic elastase (PPE) infusion compared with wild type controls [19]. There
are only two previous studies of TAFI in humans with AAA. The conclusions of both of these
studies were based on very small populations, but demonstrated an apparent increase in TAFI
activity in patients with AAA compared with control subjects [20, 21]. Due to the implication
TAFI and AAA
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of TAFI as a potentially important molecule in AAA disease, the aim of this paper was to inves-
tigate the role of inhibition of TAFI in AAA development and progression in adult Apolipo-
protein E deficient (ApoE-/-) mice. This was achieved using a monoclonal antibody
(MA-TCK26D6), which impairs the activation of TAFI mediated by plasmin, specifically pre-
venting the interaction between TAFIa and fibrin, but not affecting its binding to small mole-
cules such as OPN, C3a and C5a, and a competitive small molecule inhibitor of active TAFI,
UK-396082, which binds directly to the active catalytic site of TAFI, and thus prevents all of its
action (anti-fibrinolytic and anti-inflammatory) [22].
Materials and methods
AAA formation in the Angiotensin II model of AAA
All animal studies were carried out under the regulations laid out by the UK Home Office
under project licence 40/3523, and were approved by local ethics committees at the University
of Leeds. Animals were housed in groups of up to 5 in an individually ventilated cage system
within a purpose built animal unit. They had free access to chow diet and water for the dura-
tion of the experiment, and were maintained in a 12 hour light-dark cycle. ApoE-/- mice for
use in the study were bred in house from an established colony at the University of Leeds.
AAA were induced using the Angiotensin II model developed by Daugherty et al [23]. In brief,
male, ApoE-/- mice aged between 12–14 weeks, which were backcrossed for ten generations
on a C57Bl/6J background, were implanted with Alzet1 osmotic mini-pumps delivering
750ng/kg/min Angiotensin II, Ang II, (n = 35) or Saline control (n = 23) under general anaes-
thesia induced with inhaled isoflurane. Each pump continuously delivered treatment for 28
days. Before recovery from anaesthesia, all mice were administered with a single dose of
Buprenorphine (0.5mg/kg) via intra-peritoneal injection. Once awake, mice were placed in a
warm, clean cage, and returned to their normal cage environment once fully recovered. Mice
were monitored at least every 24 hours throughout the 28 day experiment. If any animal
showed any signs of distress prior to the end point of the experiment (such as hunched pos-
ture, partially closed eyes, changes to respiration, rough hair, withdrawal from the group), they
were sacrificed using schedule 1 approved methods.
Non-invasive monitoring of heart rate and blood pressure
In the second week following mini-pump insertion, mice underwent non-invasive monitoring
of their heart rate (HR) and blood pressure (BP) using the CODA device (Kent Scientific
Corporation).
Inhibition of TAFI in the Angiotensin II model of AAA
Once the model had been established, TAFI inhibitors (MA-TCK26D6 and UK-396082,
n = 12 in each group) were given in combination with Ang II under the same general anaes-
thetic and compared with mice receiving Ang II alone. MA-TCK26D6, or saline control, was
administered as a single intravenous injection of 436 μg per mouse (equivalent to 17 mg/kg for
an average 25 g mouse) under direct vision via the femoral vein under general anaesthesia.
UK-396082 was administered at a dose of 30 mg/kg/min via a second subcutaneous Alzet1
1004 mini-osmotic pump, which was inserted as described above. In a subsequent group,
(n = 14), due to a positive response in the prevention of development of AAA, intravenous
MA-TCK26D6 (436μg) was administered one week after the initiation of the Ang II infusion,
and compared with mice treated with a saline control injection at one week (n = 9).
TAFI and AAA
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Ultrasound scanning (USS) of the abdominal aorta
AAA progression was monitored using the Vevo12100 pre-clinical ultrasound scanner, with
VevoVasc software used to measure aortic volume and distensibility. For the Vevo12100 USS
imaging, mice were anaesthetised using volatile isoflurane. A MS550D MicroScan™ transducer
at 22–55 MHz was used for collection of the scan images, with a focus depth of 4 mm. A series
of images of the abdominal aorta were taken, both in cross section and longitudinally. Colour
Doppler and pulse wave Doppler were used to ensure the positioning of the abdominal aorta.
A 3D USS image of the suprarenal aorta was obtained for the 10.5 mm superior to the right
renal artery, in the position where any AAA would be expected to be located. An electrocardio-
gram-gated (ECG-gated) image was obtained of the longitudinal aorta in order to assess dis-
tensibility. Following the scan, the mice were recovered in a warm clean cage, before being
returned to their usual maintenance environment.
Scan images were processed remotely using VevoLab 1.7.0 and VevoVasc software. The
aortic diameter was measured in cross section at a position 5 mm proximal to the right renal
artery. Longitudinally, the aortic diameter was measured in its maximal diameter using an
ECG-gated image at maximal systole. Distensibility was calculated using an ECG-gated image
and VevoVasc software, and was a measurement of how much the aortic wall moved from the
diastolic position with each cardiac cycle. The aortic volume was calculated using a 3D recon-
struction of the 10.5 mm of the abdominal aorta proximal to the right renal artery, which is the
site of any AAA formation.
Blood collection and harvesting of the aorta
At 4 weeks post-pump implantation, mice were anaesthetised using inhaled isoflurane at 5
litres/min, then maintained at 2 litres/minute until the point of death. Whole blood was col-
lected from the inferior vena cava (IVC), onto 0.1 mol/L sodium citrate at a ratio of 9 parts
blood to 1 part citrate. Following exsanguination, the left ventricle was cannulated, and the cir-
culation perfused with 8–10 mls of phosphate buffered saline (PBS). This PBS infusion was
then followed by 5 mls of 4% paraformaldehyde, PFA (P6148, Sigma-Aldrich Co. LLC.). Mac-
roscopic imaging of the aorta was undertaken using the OPMI-PICO video micrometer (Carl
Zeiss AG).
Samples of whole blood collected from the IVC were kept on ice until processing. They
were then centrifuged at 12, 000 rcf for 20 minutes using a table-top micro-centrifuge to yield
platelet poor plasma, flash frozen in liquid nitrogen, and stored at -40˚C until analysis.
The size of the aorta was measured in-situ, and the aortic ratio calculated (being the ratio of
the abdominal aorta/the normal thoracic aorta, with a normal value of 1). The aorta was then
harvested en-bloc from the mid-thoracic level to below the left renal artery. In preparation for
histological examination, the aorta was placed in 4% PFA for a minimum of 24 hours before
processing. Samples were dehydrated on a Leica TP1020 tissue processing carousel and
embedded in paraffin. Blocks were sectioned using a Leica RM2125 microtome into 5 μm sec-
tions, and collected onto slides (4951PLUS4 Superfrost™Plus, Thermo Scientific Ltd), left to
dry at 37˚C overnight, and stored before staining. Slides were stained for elastin using a millers
elastin stain and fibrin using martius scarlet blue. Slides were imaged using an Olympus BX40
Dual View Microscope and Image Pro-Plus 8.0 at 4-20x magnifications.
Turbidity and turbidity-lysis
The turbidity and turbidity-lysis protocols which have previously been used in patient samples
[7] were adapted for use in murine plasma. Murine plasma samples (100μl, diluted 1:4 in
0.05mol/L HEPES buffer with 0.1% BSA, pH 7.4) were added to each well of a 96-well Greiner
TAFI and AAA
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bio-one microtitre plate. An activation mix (25μl) containing murine thrombin (MCT-5020-
50, Cambridge Biosciences, UK), calcium chloride (CaCl2), with or without human recombi-
nant tissue plasmingen activator (tPA) in a 0.05mol/L HEPES buffer, were added to each well.
Final concentrations per well were 0.2units/ml thrombin, 0.01mol/L CaCl2 and 0.7pmol/L
tPA. Plasma samples were run in duplicate both with and without the addition of tPA. The
absorbance was measured every 12 seconds for 90 minutes at 405nm.
Confocal microscopy
For each plasma sample, a clot containing murine fluorescein isothiocyanate-labelled (FITC-
labelled) fibrinogen was prepared. A mixture containing 30μl of plasma, CaCl2 (final concen-
tration 0.02mol/L) and murine FITC-fibrinogen (Oxford Biomedical Research, USA, final
concentration 50μg/ml) was made in TBS up to a total volume of 54μl. A reaction mix (6 μl)
containing murine thrombin (MCT-5020-50, Cambridge Biosciences, UK), final concentra-
tion 0.5 units/ml, was added to the samples. 30μl of this mixture was immediately transferred
into one side of a capillary confocal slide (80601 Thistle Scientific Ltd. UK), and the sample
monitored to ensure it crossed onto the other side of the slide by capillary action. Once pre-
pared, the slides were kept in a dark humidity chamber at room temperature for 2–4 hours in
order to ensure that the clot was completely formed. Slides were imaged using a Zeiss LSM-
700 inverted confocal microscope at 63x magnification. Images were obtained from at least 4
different parts of the clot. Images were analysed using Image J.
Statistical analysis
Raw data obtained in the laboratory were initially collected into Microsoft Excel. GraphPad
Prism v6 was used to represent the data graphically. Statistical tests were performed using IBM
SPSS Statistics v20 (SPSS Inc. Chicago, Illinois, USA) and GraphPad Prism v6. Statistically sig-
nificant results were taken as p<0.05.
All animal work was carried out within UK Home Office Regulations, under project licence
number 40/3523, and approved by the local ethics committee. The sample size for the study
was based on pilot data relating to the Ang II model in our institution, with Ang II given at a
dose of 750 ng/kg/min. Using this data, in order to detect an increase in diameter of 1.3x
(reverting from the mean for AAA in our pilot data 2.3±0.9 to the normal 1.0±0.2), with 90%
power at p<0.05, 6 animals would be needed to appreciate an effect. Given the known mortal-
ity of this model of up to 40% 12 mice were used per group. Data was analysed using Student
T-test, and presented as mean±standard deviation. Differences in survival rates were analysed
using Log-rank Mantel Cox tests.
Results
ApoE-/- mice were treated with Ang II 750 ng/kg/min or NaCl 0.9% via subcutaneous mini-
pump for 28 days. In mice surviving to 28 days (Ang II n = 21 and NaCl 0.9% n = 23) images
were taken of the aorta, and measurements taken to determine the size of both the thoracic
aorta and the supra-renal abdominal aorta. Mice were classified as AAA (n = 11) or no AAA
(n = 10), based on the aortic measurements, with AAA defined as abdominal/thoracic aortic
ratio >1.5. There was an increase in the size of the thoracic aorta in all mice treated with Ang
II; NaCl 0.9% 0.62 ± 0.08 mm, Ang II no AAA 0.81 ± 0.09 mm, Ang II AAA 1.07 ± 0.25mm
(p<0.0001). The size of the abdominal aorta also increased in all mice treated with Ang II,
with a more dramatic increase in those with a macroscopic AAA; NaCl 0.9% 0.9% 0.65 ± 0.10
mm, Ang II no AAA 0.99 ± 0.18 mm, Ang II AAA 2.60 ± 0.83 mm (p<0.0001). The aortic
ratio in mice developing AAA was 2.59 ± 1.04, whilst in control mice treated with saline it was
TAFI and AAA
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1.04 ± 0.12 (p<0.0001; See Fig 1A, 1B and 1C). There was no change in the fibrin clot structure
in mice developing AAA compared with controls (see S1 Fig). These data suggest that the
effects of Ang II on AAA formation are mediated through vascular effects that do not include
effects on fibrin clot structure at this stage of AAA development.
There was no change in the blood pressure (BP) or heart rates (HR) of mice treated with
Ang II alone, or in combination with either of the two inhibitors. HRs were within normal lim-
its in all four groups: Saline 670.8 ± 92.5 bpm, Ang II 697.4 ± 66.19bpm, Ang II and MA-
TCK26D6 690.6 ± 65.19bpm, Ang II and UK-396082 695.8 ± 78.41bpm (Fig 2A). BP readings
were also within normal limits for all four groups: Saline 107/77, Ang II 111/81, Ang II and
MA-TCK26D6 121/94 and Ang II and UK-396082 121/91 (Fig 2B).
Fig 1. Characterisation of the Angiotensin II model of AAA. Apo E-/- mice were treated with Angiotensin II
750ng/kg/min or NaCl 0.9% via subcutaneous mini-pump for 28 days. In mice surviving to 28 days (Ang II
n = 21 and NaCl 0.9% n = 23) images were taken of the aorta, and measurements taken to determine the size
of both the thoracic aorta and the supra-renal abdominal aorta. Mice were classified as AAA (n = 11) or no
AAA (n = 10), based upon the presence of an AAA (defined as aortic ratio >1.5). Panel A There was an
increase in the size of the thoracic aorta in all mice treated with Ang II. Panel B The size of the abdominal
aorta also increased in all mice treated with Ang II, with a more dramatic increase in those with a macroscopic
AAA. Panel C The aortic ratio (abdominal/thoracic aorta) in mice developing AAA. Panels D—E AAA growth
in this model was monitored using pre-clinical ultra sound scanning (Vevo 2100). At baseline, the aorta was
uniform in shape, with smooth walls (Panel D). After as little as 7 days, large AAA were evident, and, after 21
days, established AAA, with irregular, dilated lumen, could be visualised (Panel E). A—aorta, AAA—
abdominal aortic aneurysm, white dotted line demonstrates the maximal diameter of the AAA. Panel F
Representative image of control aorta at 28 days Panel G Representative image of Angiotensin II induced
AAA at 28 days T—thoracic aorta, A—abdominal aorta, RK—right kidney, LK—left kidney, AAA—abdominal
aortic aneurysm. Data is shown as mean±standard deviation, * p<0.05 compared to control by student t-test,
**** p<0.0001 compared to control by student t-test.
https://doi.org/10.1371/journal.pone.0177117.g001
TAFI and AAA
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Treatment with either of the two TAFI inhibitors (MA-TCK26D6 or UK-396082) in combi-
nation with Ang II resulted in a decrease in the mortality usually associated with this model.
The mortality of mice treated with Ang II 750 ng/kg/min via a subcutaneous mini pump
(n = 35) was 40.0%. Mortality in the NaCl 0.9% control group (n = 23) was 0%. When
MA-TCK26D6 was given in combination with Ang II (n = 12), mortality rates fell to 16.6%
(log-rank mantel cox test p = 0.16, Fig 2C and 2D). When UK-396082 was delivered in combi-
nation with Ang II (n = 12), mortality rates fell to 8.3% (log-rank mantel cox test p = 0.05; Fig
2C and 2D).
Although there was a reduction in the rate of mortality with both of the TAFI inhibitors,
the rate of AAA formation differed dependent on the inhibitor used. With MA-TCK26D6,
there was a reduction in the incidence of AAA in mice surviving to 28 days (reduced to 30.0%
from 52.4%). With UK-396082, the incidence of AAA in mice surviving to 28 days was
increased to 81.9% from 52.4% (p = 0.03). In fact, when the presence of an AAA at 28 days was
Fig 2. The effect of TAFI inhibition on mortality in the Angiotensin II model of AAA. Panel A and B Blood pressure (BP) and heart
rate (HR) measurements taken in all groups of mice in the second week of the experimental period using the CODA non-invasive BP
device. Panel C and D Mortality of mice treated with Ang II, compared with NaCl 0.9% or Ang II plus MA-TCK26D6 or UK-396082. Data
is shown as mean±standard deviation. Mortality in this model of AAA typically occurred early (Days 3–8 post initiation of Ang II infusion).
* p<0.05 compared to Angiotensin II alone by Chi-Squared testing.
https://doi.org/10.1371/journal.pone.0177117.g002
TAFI and AAA
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taken together with mortality due to rupture, the incidence of AAA was almost equivalent
between the Ang II and Ang II with UK-396082 groups (71% vs. 83%), compared with the
Ang II and MA-TCK26D6 group, where the combined response as measured by rupture or
presence of an AAA was only 42% (Fig 3A). When AAA did occur, there was no significant
difference in the size of AAA in the different groups (Aortic ratio Ang II 2.6 ± 1.0 vs. Ang II
and MA-TCK26D6 2.5 ± 0.4 vs. Ang II and UK-396082 2.7 ± 0.8; Fig 3B). Histological exami-
nation of the aortas taken from mice treated with the TAFI inhibitors, however, showed differ-
ences between the two inhibitor groups and the mice receiving only Ang II, even when
macroscopic AAA did occur. In mice treated with Ang II, there was loss of elastin from within
the structural matrix of the aortic wall, and evidence of intra-mural thrombus, with erythro-
cyte deposition and fibrin formation present in the expanded medial layer (Fig 4B). In mice
receiving both Ang II and MA-TCK26D6 that did develop AAA, there was no evidence of
intra-luminal thrombus, but there was evidence of deregulated elastin and collagen within the
internal elastic lamina and media (Fig 4C). In mice treated with Ang II in combination with
UK-396082, over 80% of mice had developed AAA at 28 days. There was gross heterogeneity
in the macroscopic and microscopic appearance of these AAA. Unlike in the aortas from mice
treated with Ang II alone, there was evidence of intra-luminal thrombus in a number of sec-
tions taken from mice treated with UK-396082. Some mice displayed evidence of complete
elastin breaks/dissections through the internal elastic lamina, whilst others showed elastin
thinning and gross aortic dilatation without an area of specific elastin breakage (Fig 4D).
Delayed treatment with MA-TCK26D6 one week after Ang II infusion (once an AAA was
established) did not affect the progression of AAA in this model. After two weeks, there was
no difference in the cross-sectional diameter of AAA in mice receiving the treatment versus
those given a control injection (MA-TCK26D6 1.93±0.62mm vs. NaCl 2.02±0.69 mm, Fig 5A).
In order to better quantify the heterogeneous expansion of the aorta, the volume of the 10.5
mm of aorta proximal to the right renal artery was reconstructed. The increase in volume over
time was also comparable between the two groups, see Fig 5B.
Using an ECG-gated ultrasound image of the abdominal aorta (taken in longitudinal sec-
tion), the distensibility of the aortic wall was measured using VevoVasc software. The overall
distensibility across both groups decreased as AAA developed (Baseline 91.92 ± 29.08 1/Mpa
falling to 53.11 ± 29.03 1/Mpa, p = 0.0001, Fig 6A). Although there was some heterogeneity
Fig 3. AAA formation is altered in the presence of a TAFI-inhibitor. Mice were treated with saline control,
NaCl 0.9%, (n = 23), Ang II (n = 35), Ang II and MA-TCK26D6 (n = 12) or Ang II and UK-396082 (n = 12) for 28
days. Panel A Incidence of AAA in each group. Panel B AAA size. Data is shown as mean±standard
deviation. * p<0.05 compared to Angiotensin II alone by Chi-Squared testing.
https://doi.org/10.1371/journal.pone.0177117.g003
TAFI and AAA
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Fig 4. Histological examination of the abdominal aorta in the Angiotensin II model of AAA following
treatment with a TAFI inhibitor. Supra-renal aortas of mice infused with Saline control, Ang II, Ang II and
MA-TCK26D6 or Ang II and UK-396082 for 28 days were fixed and stained for elastin, collagen and fibrin, and
imaged using an Olympus BX40 Dual View Microscope. Row A shows images from a mouse treated with
NaCl 0.9% (control). In mice treated with Ang II (Row B), changes characteristic of AAA are demonstrated,
with loss of elastin from within the structural matrix of the aorta (yellow arrow), and evidence of intra-mural
thrombus, with erythrocyte deposition (white arrow) and fibrin formation (black arrow) present in the expanded
medial layer. Row C shows images of aortas taken from a mouse treated with Angiotensin II and MA-
TCK26D6. In this group, only 30% of mice surviving to 28 days developed AAA, and the elastin layer remains
intact, with no thrombus seen within the aortic wall. In mice treated with Ang II 750 ng/kg/min in combination
with UK-396082 30mg/kg/min, over 80% of mice had developed AAA at 28 days. There was gross
heterogeneity in the macroscopic and microscopic appearance of these AAA. Samples from some mice even
displayed evidence of complete elastin breaks/dissections through the internal elastic lamina (blue arrow).
(Row D).
https://doi.org/10.1371/journal.pone.0177117.g004
TAFI and AAA
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between animals, there was no difference in the change of distensibility in those mice receiving
treatment with MA-TCK26D6 compared with controls (MA-TCK26D6 decreased by
37.01 ± 30.19 1/Mpa vs. NaCl decreased by 58.88 ± 37.31 1/Mpa), see Fig 6B and 6C.
Discussion
Our study has demonstrated a role for TAFI in the early stages of AAA development in the
Ang II model of AAA. By using two inhibitors that regulate different aspects of TAFI function,
our data indicate the likely relative importance of inhibition of plasmin-mediated TAFI activa-
tion compared with total TAFI inhibition. For both inhibitors, mortality was reduced in the
Ang II model of AAA. However, it was only the targeted inhibition of plasmin-mediated TAFI
activation that appeared to confer a benefit in terms of a reduction in the incidence of AAA.
Our data also indicate that the role of plasmin-mediated TAFI activation is confined to the
early stages of the model, as late treatment with the same inhibitor inferred no benefit in terms
of AAA progression.
Fig 5. There is no effect of TAFI inhibition of the growth of an established AAA in the Angiotensin II
model. AAA were induced in hyperlipidaemic mice by infusion of Ang II 750 ng/kg/min. After 1 week, mice
were treated with a single injection of either MA-TCK26D6 or NaCl control. AAA progression in both groups
was evaluated at 2 weeks post injection using Vevo2100 pre-clinical ultrasound scanning, and 3D
reconstructions of the aortic segment at risk of AAA formation were created. Panel A Aortic diameter, Panel B
Aortic volume, Panel C The process of creating the 3D aortic reconstruction. Panel D Example 3D
reconstruction showing AAA progression over time (0, 1 and 3 weeks post Angiotensin II infusion). Data is
shown as mean±standard deviation.
https://doi.org/10.1371/journal.pone.0177117.g005
TAFI and AAA
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The only previous in-vivo study of TAFI and AAA was performed in TAFI-/- mice using
the porcine pancreatic elastase infusion model, with an increase in the incidence of AAA and
the rupture rate in mice deficient in TAFI [19]. There are advantages and disadvantages to dif-
ferent animal models for AAA. The Ang II model was used for this study as it better replicates
the thrombosis and fibrinolysis aspects of the AAA disease process, that is, it results in the pro-
duction of a thrombus with a subsequent inflammatory response [23, 24]. We showed that the
mortality associated with this model was decreased when MA-TCK26D6 was delivered at the
initiation of the Ang II infusion, and this effect was also demonstrated using an inhibitor of all
active TAFI, UK-396082. This implicates the importance of thrombus formation in this
model. The initial stage of AAA development in this model involves dissection of the intima,
followed by the development of an intra-mural thrombus. For both MA-TCK26D6 and UK-
396082, the inhibition of TAFIa will lead to a reduction in the deposition and/or an increase in
the resolution of the intra-mural thrombus that develops following aortic dissection. In sup-
port of this, there was no evidence of intra-mural thrombus on histology after 28 days. As mor-
tality in this model classically occurs within the first 7 days after initiation of the Ang II
infusion, we hypothesise that the formation of intra-mural thrombus early in the Ang II model
of AAA increases the incidence of complete aortic dissection, and does not provide, as may be
expected, a protective mechanism against aortic rupture.
Fig 6. Aortic distensibility decreases with AAA formation, but is not affected by TAFI-inhibition, in the
Angiotensin II model of AAA. The aorta was imaged in longitudinal section using the Vevo2100 scanner,
and the distensibility measured using ECG-gated images and VevoVasc software. Panel A shows aortic wall
distensibility in all mice with AAA (MA-TCK26D6 treated and sham treated). One week following initiation of
Ang II infusion, mice received either MA-TCK26D6 or control (NaCl 0.9%) as an IV injection via the femoral
vein. Panel B and C There was no difference in the change of distensibility by week 3 in mice receiving
treatment with MA-TCK26D6 at 1 week compared with controls (data shown is change in distensibility
between week 1 and week 3). Data is shown as mean±standard deviation, *** p = 0.001 compared to
baseline by student t-test.
https://doi.org/10.1371/journal.pone.0177117.g006
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Although inhibition of TAFI via either route resulted in a survival advantage in this model,
the incidence of AAA was affected in different ways dependent on the route of inhibition.
When UK-396082 was administered in conjunction with Ang II, there was an increase in the
incidence of AAA at 28 days, however, once the reduced rate of rupture in this group was
taken into account, there was no overall change in Ang II response, a result that is more in
keeping with the previous study in the TAFI-/- mouse [19]. However, when plasmin-mediated
activation of TAFI was inhibited using MA-TCK26D6, there was a reduction in the incidence
of AAA, as indicated by both a reduction in rupture and also a reduction in the presence of an
AAA at 28 days. MA-TCK26D6, whilst inhibiting the effects of TAFIa on fibrinolysis, pre-
serves all of TAFIa’s anti-inflammatory properties. This leads to the hypothesis that once an
intra-mural thrombus has formed, the driver for the ongoing development of AAA may be
more related to inflammatory processes rather than ongoing thrombosis. When no inhibitor is
used, there is evidence of intra-mural thrombus formation, and then a subsequent inflamma-
tory response, which drives the breakdown of elastin within the vessel wall and ultimately
results in AAA formation. When the UK-396082 inhibitor was used, the initial intra-mural
thrombus would not have been as stable or long lasting as in the control. However, due to the
inhibition of TAFIa’s anti-inflammatory properties in addition to its anti-fibrinolytic proper-
ties, we hypothesise that in this case, there would be unregulated inflammation at the site of
the initial insult. Even in the absence of a thrombus to drive an ongoing proteolytic reaction,
this unregulated inflammation would be sufficient to destroy the elastin of the vessel wall, and
thus lead to AAA formation. The opposite was seen in mice receiving MA-TCK26D6, the
inhibitor of plasmin-mediated TAFI activation. In this instance, again, the inhibition of TAFI
would have prevented the formation of an intra-mural thrombus. However, in these mice, the
anti-inflammatory properties of TAFI against small molecule inhibitors such as C3a, C5a and
OPN would have remained intact, and there should therefore have been normal regulation of
any inflammatory response by TAFIa. We hypothesise that in this case, the rapid resolution of
any intra-mural thrombus and the relatively reduced inflammatory response (in comparison
to UK-396082), result in resolution of the initial defect without subsequent aneurysm forma-
tion. This contrasts with the conclusion of the only previous in-vivo study. These authors
showed that in their model, the administration of PPE into OPN-/- mice did not result in
enhanced AAA formation, implying that it was not an unregulated inflammatory response
that resulted in AAA formation in the TAFI-/- mice. Further, the addition of tranexamic acid
(a lysine analogue, which results in a reduction in the activation and action of plasmin),
reduced AAA formation and abolished AAA rupture in the TAFI-/- [19], implying that it was
the effects of plasmin that resulted in the formation and rupture of AAA. It may be that the
important pathological processes in the formation of experimental AAA differ between the
models, with inflammation following thrombus formation being a more key factor in the
breakdown of the aortic wall, and thus AAA formation, in the Ang II model compared with
the elastase model. Indeed, in a previous study, when Ang II was infused into OPN-/-ApoE-/-
mice, they were protected from AAA formation [25], again implying an important role for
inflammation in this particular model of AAA.
Given the positive effects of the inhibition of plasmin-mediated TAFI activation on the for-
mation of AAA in-vivo, we next studied if this could affect the progression of AAA in this
model. To do this, mice were administered with a dose of MA-TCK26D6 (or saline control)
one week after the initiation of the Ang II infusion, once AAA had already been established.
As, based on our own pilot data, not all ApoE-/- mice treated with Ang II were expected to
develop AAA, mice underwent abdominal ultrasound scans prior to any injection in order to
be able to measure the pre-treatment AAA size. There was no mortality following either injec-
tion. There was no effect of plasmin-mediated TAFI inhibition on AAA progression in this
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model; the change in AAA size was comparable between the treatment group and the controls.
There was a reduction in the distensibility of the aorta, as would be expected with AAA forma-
tion, in both groups, and again, there was no effect on the change in aortic distensibility with
MA-TCK26D6 treatment. Together, these data show that later in the Ang II model of AAA,
inhibition of TAFI does not have any effect on AAA development. It is likely that after one
week, the pathological processes at work in this model are already too well established to be
influenced by the inhibition of TAFI activation. This further supports our hypothesis that, in
the Ang II model of AAA, it is the combination of initial intra-mural thrombus formation and
an inflammatory response that drives AAA formation. Once thrombus is formed, and the
inflammatory response has been initiated, the addition of an inhibitor that prevents further
thrombus formation has no effect on outcome.
Given that late treatment with MA-TCK26D6 did not affect AAA progression, it seems
unlikely that these data will be directly transferable to human disease, as treatment for AAA
can only be initiated following diagnosis, once the disease process is already underway. How-
ever, our data demonstrate that early inhibition of plasmin-mediated TAFI activation confers
a survival advantage and reduces AAA formation in an Ang II model of AAA. Further studies
are required to investigate the role of thrombosis, fibrinolysis and subsequent inflammatory
response in the early stages of AAA.
Supporting information
S1 Fig. Fibrin clot structure in the Angiotensin II model of AAA. Turbidity and turbidity
lysis was performed using plasma from mice with AAA (n = 7) and mice treated with saline
control (n = 8). There was no difference in the time taken to reach the maximum OD (11.11
±2.57 mins vs. 13.46±2.32 mins, panel A), the maximum OD (0.10±0.07 vs. 0.09±0.02, panel
B) or the time to half lysis (50.59±23.31 mins vs. 41.21±14.93 mins, panel C). Fibrin clots were
formed which incorporated FITC-labelled fibrinogen, in order to allow for the microscopic
study of the fibrin clot structure. This confirmed that there was no difference in the fibrin fibre
density in mice treated with Ang II developing AAA and controls (286.3±260.4 fibres/100μm2
vs. 361.3±217.2 fibres/100μm2, panel D). Sample images of the fibrin clot structure are shown
in Panel E.
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